LT3442580T - Cholestazinių ir fibrozinių ligų gydymo būdai - Google Patents
Cholestazinių ir fibrozinių ligų gydymo būdaiInfo
- Publication number
- LT3442580T LT3442580T LTEP17710285.2T LT17710285T LT3442580T LT 3442580 T LT3442580 T LT 3442580T LT 17710285 T LT17710285 T LT 17710285T LT 3442580 T LT3442580 T LT 3442580T
- Authority
- LT
- Lithuania
- Prior art keywords
- cholestatic
- treatment
- methods
- fibrotic diseases
- fibrotic
- Prior art date
Links
- 230000001587 cholestatic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003176 fibrotic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305425 | 2016-04-11 | ||
| PCT/EP2017/055878 WO2017178172A1 (en) | 2016-04-11 | 2017-03-13 | Methods of treatment for cholestatic and fibrotic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3442580T true LT3442580T (lt) | 2020-12-28 |
Family
ID=55755536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP17710285.2T LT3442580T (lt) | 2016-04-11 | 2017-03-13 | Cholestazinių ir fibrozinių ligų gydymo būdai |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US20170290812A1 (https=) |
| EP (3) | EP3777854B1 (https=) |
| JP (1) | JP6894923B2 (https=) |
| KR (1) | KR102431257B1 (https=) |
| CN (1) | CN109069648B (https=) |
| AU (1) | AU2017249602B2 (https=) |
| DK (2) | DK3777855T3 (https=) |
| EA (2) | EA201892298A1 (https=) |
| ES (3) | ES2935185T3 (https=) |
| HR (1) | HRP20201954T1 (https=) |
| HU (2) | HUE052886T2 (https=) |
| IL (1) | IL262052B (https=) |
| LT (1) | LT3442580T (https=) |
| MD (1) | MD3442580T2 (https=) |
| MX (1) | MX384261B (https=) |
| MY (1) | MY195437A (https=) |
| PH (1) | PH12018502142B1 (https=) |
| PL (1) | PL3442580T3 (https=) |
| PT (2) | PT3442580T (https=) |
| SG (2) | SG11201808402RA (https=) |
| SI (1) | SI3442580T1 (https=) |
| WO (1) | WO2017178172A1 (https=) |
| ZA (1) | ZA201807389B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6894923B2 (ja) | 2016-04-11 | 2021-06-30 | ジェンフィＧｅｎｆｉｔ | 胆汁うっ滞性及び線維性の疾患の処置方法 |
| JP2019513762A (ja) * | 2016-04-11 | 2019-05-30 | ジェンフィＧｅｎｆｉｔ | 胆汁うっ滞及び線維症の処置方法 |
| WO2018167103A1 (en) | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| BR112019019519A2 (pt) * | 2017-03-21 | 2020-04-22 | Novalead Pharma Inc | agente terapêutico para a inibição de fosfodiesterase e seus distúrbios relacionados |
| JP7365054B2 (ja) * | 2017-11-17 | 2023-10-19 | ケスター，ヒューバート | リンパ管平滑筋腫症及びその他の疾患に使用するための［２－［（５－ニトロ－１，３－チアゾール－２－イル）カルバモイル］フェニル］エタノエート |
| EP3639822A1 (en) * | 2018-10-15 | 2020-04-22 | Universität Regensburg | Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion |
| JP7631217B2 (ja) | 2019-04-10 | 2025-02-18 | ジェンフィット | 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法 |
| CA3130518A1 (en) * | 2019-04-12 | 2020-10-15 | Nicolas STANKOVIC-VALENTIN | Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress |
| CN110205302B (zh) * | 2019-06-24 | 2021-03-23 | 扬州大学 | 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用 |
| CN110478357A (zh) * | 2019-07-23 | 2019-11-22 | 哈尔滨医科大学 | 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用 |
| CN110368498A (zh) * | 2019-08-26 | 2019-10-25 | 瑞希(重庆)生物科技有限公司 | 一种促进伤口愈合的制剂及其制备方法 |
| JP7741800B2 (ja) | 2019-10-28 | 2025-09-18 | ジェンフィット | 抗酸化性質を有する併用療法 |
| CN113398125B (zh) * | 2020-03-16 | 2024-05-03 | 绍兴君科臻元医药科技有限公司 | 替唑尼特药物组合物及其医药用途 |
| KR20230110284A (ko) * | 2020-11-17 | 2023-07-21 | 장피트 | 간부전 치료 방법 |
| CN116507343A (zh) * | 2020-11-17 | 2023-07-28 | 基恩菲特公司 | 治疗肝衰竭的方法 |
| CN115197164B (zh) * | 2021-04-12 | 2025-04-01 | 杜心赟 | 新型噻唑类化合物及其制备方法和用途 |
| AU2022271607A1 (en) * | 2021-05-11 | 2023-10-26 | Genfit | Nitazoxanide in the treatment of sepsis |
| CN116077502B (zh) * | 2021-11-05 | 2025-12-23 | 广州医科大学附属妇女儿童医疗中心 | 叶酸在预防、诊断和治疗胆道闭锁中的应用 |
| AU2023355753A1 (en) * | 2022-10-04 | 2025-04-03 | Genfit | Nitazoxanide for the treatment of hepatic impairment |
| CN116911513B (zh) * | 2023-02-07 | 2024-07-26 | 中国药科大学 | 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用 |
| WO2025063816A1 (ko) * | 2023-09-21 | 2025-03-27 | 오토텔릭바이오 주식회사 | 티아졸 유도체 화합물을 포함하는 자궁 섬유화증 치료용 조성물 |
| CN117838690B (zh) * | 2023-10-09 | 2024-09-13 | 中国药科大学 | 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| GB1440212A (en) | 1973-08-29 | 1976-06-23 | Phavic Sprl | Derivatives of 2-phenoxyacetamido-5-nitrothiazoles |
| US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| US5965590A (en) | 1994-09-08 | 1999-10-12 | Romark Lab Lc | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
| MX9604483A (es) | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas. |
| US5935591A (en) | 1998-01-15 | 1999-08-10 | Romark Laboratories, L.C. | Method for treatment of equine protozoal myeloencephalitis with thiazolides |
| US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| WO2002051442A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| ZA200602755B (en) | 2003-09-06 | 2007-06-27 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| UA90864C2 (en) | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
| CA2618646A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| EP1971594A2 (en) | 2005-11-21 | 2008-09-24 | Biogen Idec MA Inc. | Substituted pyrazalones |
| CA2636527C (en) * | 2006-01-09 | 2016-05-17 | Romark Laboratories, L.C. | Viral hepatitis treatment |
| US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| GB0619500D0 (en) | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
| ES2550755T3 (es) | 2007-08-03 | 2015-11-12 | Romark Laboratories, L.C. | Compuestos de tiazolida sustituidos con alquilsulfonilo |
| US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
| KR101045572B1 (ko) | 2007-08-14 | 2011-07-01 | 주식회사 엘지화학 | Ｃｌｏｓｔｒｉｄｉｕｍ ｐｒｏｐｉｏｎｉｃｕｍ 유래의프로피오닐―ＣｏＡ 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법 |
| JP5715820B2 (ja) | 2007-09-18 | 2015-05-13 | スタンフォード ユニバーシティー | フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 |
| US9149463B2 (en) * | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| US20100016262A1 (en) | 2007-10-18 | 2010-01-21 | Yale University | Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis |
| EP2408449A4 (en) * | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS |
| NZ596538A (en) | 2009-05-12 | 2014-04-30 | Romark Lab Lc | Haloalkyl heteroaryl benzamide compounds |
| CN108042535A (zh) | 2009-06-26 | 2018-05-18 | 罗马克实验室有限公司 | 用于治疗流感的化合物和方法 |
| KR101961601B1 (ko) | 2009-11-16 | 2019-03-25 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법 |
| US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| EP2609095A4 (en) | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| AU2011323682B2 (en) | 2010-11-01 | 2016-06-23 | Romark Laboratories L.C. | Alkylsulfinyl-substituted thiazolide compounds |
| EP2680859B1 (en) | 2011-03-02 | 2022-04-27 | Jerome Schentag | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| CN107096032A (zh) | 2011-05-16 | 2017-08-29 | 罗马克实验室有限公司 | 在有需要的对象中刺激免疫应答的方法 |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2013202269A1 (en) * | 2011-10-26 | 2013-05-16 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| WO2013082469A2 (en) | 2011-12-02 | 2013-06-06 | University Of Vermont And State Agricultural College | Methods and compositions for treating infections |
| EP2890370B1 (en) | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
| MX2017006083A (es) | 2014-11-11 | 2017-11-08 | Romark Laboratories Lc | Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma. |
| US20190070154A1 (en) | 2015-06-24 | 2019-03-07 | Duke University | New methods of use for an anti-diarrhea agent |
| KR102410951B1 (ko) | 2016-04-11 | 2022-06-20 | 장피트 | 담즙정체성 및 섬유증 질환의 치료 방법 |
| JP2019513762A (ja) | 2016-04-11 | 2019-05-30 | ジェンフィＧｅｎｆｉｔ | 胆汁うっ滞及び線維症の処置方法 |
| JP6894923B2 (ja) | 2016-04-11 | 2021-06-30 | ジェンフィＧｅｎｆｉｔ | 胆汁うっ滞性及び線維性の疾患の処置方法 |
-
2017
- 2017-03-13 JP JP2018553102A patent/JP6894923B2/ja active Active
- 2017-03-13 HU HUE17710285A patent/HUE052886T2/hu unknown
- 2017-03-13 HR HRP20201954TT patent/HRP20201954T1/hr unknown
- 2017-03-13 SG SG11201808402RA patent/SG11201808402RA/en unknown
- 2017-03-13 ES ES20194458T patent/ES2935185T3/es active Active
- 2017-03-13 EP EP20194454.3A patent/EP3777854B1/en active Active
- 2017-03-13 ES ES20194454T patent/ES2928408T3/es active Active
- 2017-03-13 WO PCT/EP2017/055878 patent/WO2017178172A1/en not_active Ceased
- 2017-03-13 PL PL17710285T patent/PL3442580T3/pl unknown
- 2017-03-13 LT LTEP17710285.2T patent/LT3442580T/lt unknown
- 2017-03-13 HU HUE20194458A patent/HUE060671T2/hu unknown
- 2017-03-13 PT PT177102852T patent/PT3442580T/pt unknown
- 2017-03-13 EA EA201892298A patent/EA201892298A1/ru unknown
- 2017-03-13 DK DK20194458.4T patent/DK3777855T3/da active
- 2017-03-13 CN CN201780023160.XA patent/CN109069648B/zh active Active
- 2017-03-13 PT PT201944584T patent/PT3777855T/pt unknown
- 2017-03-13 EP EP17710285.2A patent/EP3442580B1/en active Active
- 2017-03-13 PH PH1/2018/502142A patent/PH12018502142B1/en unknown
- 2017-03-13 ES ES17710285T patent/ES2839453T3/es active Active
- 2017-03-13 SG SG10202004425XA patent/SG10202004425XA/en unknown
- 2017-03-13 DK DK17710285.2T patent/DK3442580T3/da active
- 2017-03-13 AU AU2017249602A patent/AU2017249602B2/en active Active
- 2017-03-13 KR KR1020187032681A patent/KR102431257B1/ko active Active
- 2017-03-13 MX MX2018012287A patent/MX384261B/es unknown
- 2017-03-13 EP EP20194458.4A patent/EP3777855B1/en active Active
- 2017-03-13 EA EA202191466A patent/EA202191466A1/ru unknown
- 2017-03-13 MD MDE20190213T patent/MD3442580T2/ro unknown
- 2017-03-13 US US15/457,158 patent/US20170290812A1/en not_active Abandoned
- 2017-03-13 MY MYPI2018001719A patent/MY195437A/en unknown
- 2017-03-13 SI SI201730549T patent/SI3442580T1/sl unknown
- 2017-12-11 US US15/837,889 patent/US10130612B2/en active Active
- 2017-12-14 US US15/842,234 patent/US10130613B2/en active Active
- 2017-12-14 US US15/841,981 patent/US10117856B2/en active Active
- 2017-12-14 US US15/841,777 patent/US10117855B2/en active Active
-
2018
- 2018-09-19 US US16/135,945 patent/US20190000813A1/en not_active Abandoned
- 2018-10-02 IL IL262052A patent/IL262052B/en unknown
- 2018-11-05 ZA ZA2018/07389A patent/ZA201807389B/en unknown
-
2020
- 2020-06-24 US US16/910,756 patent/US11103484B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807389B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| ZA202006746B (en) | Methods of treatment | |
| IL253244A0 (en) | Methods for treating retinal diseases | |
| ZA201807390B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| HUS2500033I1 (hu) | Intrahepatikus kolesztázisos betegségek kezelése | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| IL274541A (en) | A method for treating diseases of the digestive tract using Tradifitant | |
| IL249894A0 (en) | Targeted medical nanoparticles and methods for their preparation and use | |
| ZA201705877B (en) | Method of treating diseases | |
| ZA201808360B (en) | Treatment of intrahepatic cholestatic diseases | |
| IL253847A0 (en) | Methods of treating diseases | |
| GB201416832D0 (en) | Methods of treatment | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| GB201602802D0 (en) | Method of treatment | |
| EP3151824A4 (en) | Methods of treating neurodevelopmental diseases and disorders | |
| HK40001765A (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| GB201500555D0 (en) | Method and device for the treatment of diseases | |
| EP3193935A4 (en) | Treatment of fibrotic diseases | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201801249D0 (en) | Methods of treatment | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer | |
| AU2014902173A0 (en) | Methods of treating neurodevelopmental diseases and disorders | |
| GB201414023D0 (en) | Treatment of autoimmune diseases |